Categories
Aarti Drugs Limited — Updates, 16-05-2026: Press Release
16-05-2026 · 02:33 pm
Aarti Drugs reported FY26 PAT up 16% to Rs 194.9 Cr, with revenue at Rs 2,567.7 Cr (+7%). Q4 saw strong sequential recovery: revenue Rs 721.1 Cr (+20% QoQ), EBITDA Rs 96.6 Cr (+72% QoQ), driven by Sayakha facility scale-up and better product mix. Formulations and Specialty Chemicals showed strong segment growth.
No comments yet. Be the first to comment!